<DOC>
	<DOCNO>NCT00467402</DOCNO>
	<brief_summary>This study demonstrate efficacy agomelatine ( AGO178 ) 25 mg 50 mg prevention relapse patient Major Depressive Disorder ( MDD ) . Eligible patient undergo open-label treatment 20 26 week , depend response treatment . Patients demonstrate stable response end open-label treatment phase assign receive agomelatine placebo 52 week .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability Agomelatine Prevention Relapse Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>S 20098</mesh_term>
	<criteria>Male female adult , 18 70 year age , inclusive Diagnosis Major Depressive Disorder , recurrent episode , accord Diagnostic Statistical Manual Mental Disorders 4th Edition ( DSMIV ) criteria A history least two previous episode Major Depression plus current episode Hamilton Depression Rating Scale ( HAMD17 ) total score â‰¥ 22 Screening Baseline History bipolar disorder ( I II ) , schizophrenia , schizoaffective disorder , eat disorder , obsessive compulsive disorder Any current Axis I disorder major depressive disorder focus treatment Substance alcohol abuse last 30 day , dependence last 6 month Use psychoactive medication screen visit Patients previously treat agomelatine Female patient childbearing potential use effective contraception Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>agomelatine , Major Depressive Disorder , MDD , depression</keyword>
</DOC>